SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Aiden Haghikia, Ralf Gold, Multiple sclerosis: TOWER confirms the efficacy of oral teriflunomide in MS, Nature Reviews Neurology, 2014, 10, 4, 183

    CrossRef

  2. 2
    Martin Marziniak, Neue Therapieoptionen, MMW - Fortschritte der Medizin, 2014, 156, 23, 69

    CrossRef

  3. 3
    Christian Confavreux, Paul O'Connor, Giancarlo Comi, Mark S Freedman, Aaron E Miller, Tomas P Olsson, Jerry S Wolinsky, Teresa Bagulho, Jean-Luc Delhay, Deborah Dukovic, Philippe Truffinet, Ludwig Kappos, Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial, The Lancet Neurology, 2014, 13, 3, 247

    CrossRef

  4. 4
    Amit Bar-Or, Teriflunomide (Aubagio®) for the treatment of multiple sclerosis, Experimental Neurology, 2014,

    CrossRef

  5. 5
    Amit Bar-Or, Andrew Pachner, Francoise Menguy-Vacheron, Johanne Kaplan, Heinz Wiendl, Teriflunomide and Its Mechanism of Action in Multiple Sclerosis, Drugs, 2014, 74, 6, 659

    CrossRef

  6. 6
    Gillian M. Keating, Karly P. Garnock-Jones, Teriflunomide: a guide to its use in relapsing–remitting multiple sclerosis in the EU, Drugs & Therapy Perspectives, 2014, 30, 7, 241

    CrossRef

  7. 7
    Amanda L. Hernandez, Kevin C. O’Connor, David A. Hafler, The Autoimmune Diseases, 2014,

    CrossRef

  8. 8
    Tiffany J. Braley, Benjamin M. Segal, B-Cell Targeting Agents in the Treatment of Multiple Sclerosis, Current Treatment Options in Neurology, 2013, 15, 3, 259

    CrossRef

  9. 9
    Dennis J. Cada, Terri L. Levien, Danial E. Baker, Dimethyl Fumarate, Hospital Pharmacy, 2013, 48, 8, 668

    CrossRef

  10. 10
    Aran Groves, Yasuyuki Kihara, Jerold Chun, Fingolimod: Direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy, Journal of the Neurological Sciences, 2013, 328, 1-2, 9

    CrossRef

  11. 11
    C. Warnke, G. Meyer Zu Hörste, T. Menge, O. Stüve, H.-P. Hartung, H. Wiendl, B.C. Kieseier, Teriflunomid zur Behandlung der Multiplen Sklerose, Der Nervenarzt, 2013, 84, 6, 724

    CrossRef

  12. 12
    Dennis J. Cada, Kendra Demaris, Terri L. Levien, Danial E. Baker, Teriflunomide, Hospital Pharmacy, 2013, 48, 3, 231

    CrossRef

  13. 13
    Aaron E Miller, Teriflunomide efficacy, safety and tolerability in patients with relapsing forms of multiple sclerosis, Neurodegenerative Disease Management, 2013, 3, 5, 467

    CrossRef

  14. 14
    Karly P. Garnock-Jones, Teriflunomide: A Review of Its Use in Relapsing Multiple Sclerosis, CNS Drugs, 2013, 27, 12, 1103

    CrossRef

  15. 15
    Li Li, Jingchun Liu, Thomas Delohery, Donghui Zhang, Christopher Arendt, Catherine Jones, The effects of teriflunomide on lymphocyte subpopulations in human peripheral blood mononuclear cells in vitro, Journal of Neuroimmunology, 2013, 265, 1-2, 82

    CrossRef

  16. 16
    Toru Koda, Topics of the 29th European Committee for Treatment and Research in Multiple Sclerosis Congress in Copenhagen, Denmark, 2013, Clinical and Experimental Neuroimmunology, 2013, 4, 3
  17. 17
    R. A. Fuentealba, J. Marasa, M. I. Diamond, D. Piwnica-Worms, C. C. Weihl, An aggregation sensing reporter identifies leflunomide and teriflunomide as polyglutamine aggregate inhibitors, Human Molecular Genetics, 2012, 21, 3, 664

    CrossRef

  18. 18
    Laura E. Bowie, Wendi A. Roscoe, Ed M.K. Lui, Robin Smith, Stephen J. Karlik, Effects of an aqueous extract of North American ginseng on MOG(35–55)-induced EAE in mice, Canadian Journal of Physiology and Pharmacology, 2012, 90, 7, 933

    CrossRef

  19. 19
    Stephen Krieger, Multiple Sclerosis Therapeutic Pipeline: Opportunities and Challenges, Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine, 2011, 78, 2